Capricor Therapeutics Under Legal Scrutiny
In a recent development, Capricor Therapeutics, Inc. is embroiled in a class action securities lawsuit. The firm Levi & Korsinsky, LLP, representing investors, has launched the suit alleging securities fraud that negatively impacted stakeholders within a specific timeline.
Understanding the Class Action Lawsuit
This legal action seeks to recover losses for investors who faced detrimental effects from alleged fraudulent actions conducted by the company. Specifically, it covers incidents from October 9, 2024, to July 10, 2025.
What We Know About the Allegations
The lawsuit focuses on the misrepresentation of Capricor's lead cell therapy candidate, deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). During the lawsuit's timeline, the company allegedly misled investors about obtaining a Biologics License Application (BLA) for the drug.
Material Information and Misleading Statements
According to sources, the defendants provided excessively positive information regarding deramiocel’s approval prospects while concealing significant adverse facts, particularly regarding the four-year safety and efficacy data from its Phase 2 HOPE-2 trial. On July 11, 2025, Capricor disclosed receiving a Complete Response Letter (CRL) from the FDA that denied the BLA, stating that it did not meet the necessary requirements for substantial evidence of effectiveness and additional clinical data was needed.
Impact on Investors
As a result of this announcement, Capricor's stock experienced a sharp decline. On July 10, 2025, the stock was valued at $11.40 per share, plummeting to $7.64 the following day. This significant drop has raised concerns among investors about the integrity and reliability of the information provided by the company.
How Investors Can Participate
For those who have incurred losses during the specified period, participation in this class action provides a potential avenue for recovery. Interested parties are urged to act quickly, as the deadline to apply as a lead plaintiff is fast approaching.
Legal Representation and Next Steps
Joseph E. Levi, representing the plaintiffs, has made it clear that being a lead plaintiff is not a prerequisite for participating in any potential recovery from the lawsuit. Investors can reach out to Levi & Korsinsky for more information and assistance with claims.
Why Choose Levi & Korsinsky?
The firm has an impressive 20-year history of advocating for investor rights and has a proven record of facilitating significant recoveries for shareholders. With a dedicated team of experts, they specialize in securities litigation and aim to provide the best possible representation for individuals affected by corporate misconduct.
Contact Information
Investors seeking further clarification or wishing to participate in this class action lawsuit can reach out to Levi & Korsinsky:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: jlevi@levikorsinsky.com
Phone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com
Frequently Asked Questions
What is the Capricor lawsuit about?
The lawsuit pertains to allegations of securities fraud that negatively impacted investors between October 2024 and July 2025.
How can I participate in the class action?
Individuals can contact Levi & Korsinsky to learn about the steps required to participate.
What damages are being sought?
The lawsuit aims to recover losses sustained by investors due to misleading information from the company.
Is there a cost to participate?
Participation in the class action is at no cost to investors; fees are typically covered by the recovery amount.
Who are Levi & Korsinsky?
Levi & Korsinsky is a law firm specializing in securities litigation with a notable track record of success for shareholders.
